VIP, PACAP, and related peptides
Subtitle: from gene to therapy
By: edited by Hubert Vaudry and Marc Laburthe.
Contributors: Vaudry, Hubert.; Laburthe, Marc.
Series: Annals of the New York Academy of Sciences -- v. 1070
Publisher: Published by Blackwell Pub. on behalf of the New York Academy of Sciences
Published: 2006
Place of publication: Boston, Mass
Language: eng
Number of pages: 633
ISBN-13: 9781573315500
Subjects: Neuropeptides; Neuropeptides -- Physiological effect; Neuropeptides; Vasoactive Intestinal Peptide; Pituitary Adenylate Cyclase-Activating Polypeptide
Description: "This volume provides an overview on the biochemistry, physiology, and pharmacology of vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and related peptides. VIP and PACAP are undoubtedly among the most fascinating neuropeptides ever identified. They belong to the largest family of regulatory peptides, which comprises several other prominent neuroendocrine peptides including secretin (the first peptide hormone that has been identified), glucagon, and growth hormone-releasing hormone. The structural and physiological relationships of these peptides as well as their receptors provide a unique model for investigating the processes of molecular evolution leading to the diversification of multigene families. The primary structures of VIP and PACAP have been remarkably well conserved across vertebrates, suggesting that these peptides must be involved in vital functions throughout the animal kingdom. Indeed, VIP and PACAP appear to be implicated in a large array of physiological processes such as development; growth; endocrine, cardiovascular, respiratory, reproductive and digestive functions; immune responses; and circadian rhythms. There is also clear evidence that VIP and PACAP exert both trophic and antiproliferative effects on normal and tumor cells. The beneficial influence of VIP and PACAP agonists and antagonists in various pathological states including heart failure, ischemia, asthma, impotence, and cancer has motivated the development of novel selective VIP or PACAP ligands that could potentially be used as antihypertensive, neuroprotective, bronchodilatory, vasodilatory, and/or antiproliferative drugs. The occurrence of multiple VIP/PACAP receptor subtypes and splice variants that exhibit tissue-specific expression and possess differential affinity for various ligands generates hopes for the development of new therapeutic agents that could act selectively on the desired target cells."--Publisher's website.
Notes: Includes bibliographical references and index.